Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07253285 · ClinicalTrials.gov registry record · Phase 3

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

A Phase 3 study of Obesity and Overweight, sponsored by Novo Nordisk A/S.

Recruiting
Registry status
Phase 3
Development phase
460
Enrollment target
20
Study locations

NCT07253285: Recruiting Phase 3 study of Obesity and Overweight, sponsored by Novo Nordisk A/S.

NCT07253285 is a Phase 3 study of Obesity and Overweight that is actively recruiting participants, run by Novo Nordisk A/S. The registered enrollment target is 460 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (44% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07253285, a Phase 3 study of Obesity and Overweight, is actively recruiting participants, sponsored by Novo Nordisk A/S.

RECRUITING
Registry status
Phase 3
Development phase
460 participants
Enrollment target
20
Study locations

Study Summary

This study will look at how well CagriSema and cagrilintide help children and adolescents with excess body weight lose weight. The study has 2 parts: main and extension study. In the main study, participants will either get CagriSema (a new study drug), cagrilintide (a new study drug), semaglutide (a drug that doctors can already prescribe to adolescents and adults) or placebo (a placebo looks like the treatment being tested, but doesn't have any active ingredients in it). Which treatment participants will get is decided by chance. Participants who get semaglutide in the main study will not take part in the extension study. If participants take part in the extension study, they will get either CagriSema or cagrilintide in this part of the study. Like all drugs, the study drugs may have side effects. The total time participants will be in the main study is about 1 year and 6 months. If participants take part in the extension study, the total time is about 4 years and 10 months.

Primary Outcome

Measured in percentage (%).

Conditions Studied

Obesity Overweight

Interventions

  • DRUG Semaglutide
  • DRUG Cagrilintide
  • DRUG Placebo cagrilintide
  • DRUG Placebo semaglutide

Study Locations (20)

Georgia

  • Children's Healthcare Atlanta - Atlanta
  • Columbus Research Foundation - Columbus
  • Accel Research Sites-NeuroStudies - Decatur
  • Eastside Bariatric and Gen Surg - Snellville

Florida

  • Encore Medical Research LLC - Hollywood
  • Jacksonville Ctr for Clin Res - Jacksonville
  • Encore Medical Research of Weston - Weston

New York

  • UBMD Physicians Group - Pediatrics - Conventus - Buffalo
  • SUNY Upstate Medical Univ - Syracuse - Syracuse
  • Advantage Clinical Trials - The Bronx

Minnesota

  • University of Minnesota - Minneapolis
  • AES Minneapolis DRS - Richfield

California

  • Neighborhood Healthcare - Escondido

Idaho

  • Solaris Clinical Research - Meridian

Indiana

  • IU Health - Riley Physicians Endo-Diab - Indianapolis

Kansas

  • Cotton O'Neil Clinical Research Center - Topeka

Trial Details

FieldValue
Enrollment Target 460 participants
Start Date 2026-01-08
Est. Completion 2033-09-20
Phase Phase 3
Novo Nordisk A/S

431 total trials

What NCT07253285 shows while recruiting

NCT07253285 is an interventional study that assigns participants to a tested intervention. The registered 460 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (44% lower).

The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 4 interventions - of which Semaglutide is the first listed.

NCT07253285 names 20 study sites across 12 states, led by Georgia, Florida, New York.

Frequently Asked Questions

What is clinical trial NCT07253285 about?

NCT07253285 is a clinical study titled "A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight". This study will look at how well CagriSema and cagrilintide help children and adolescents with excess body weight lose weight. The study has 2 parts: main and extension study. In the main study, participants will either get CagriSema (a new study drug), cagrilintide (a new study drug), semaglutide (...

What is the current status of trial NCT07253285?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 460 participants. The study started on 2026-01-08. Estimated completion is 2033-09-20.

What conditions does trial NCT07253285 study?

This clinical trial studies the following conditions: Obesity, Overweight.

What interventions are being tested in trial NCT07253285?

The interventions under investigation include: Semaglutide (DRUG), Cagrilintide (DRUG), Placebo cagrilintide (DRUG), Placebo semaglutide (DRUG).

Who is sponsoring clinical trial NCT07253285?

This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07253285 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Idaho, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07253285's enrollment target sits among peer trials

460 149th of 1053 higher than 903 of 1,053 other Obesity trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02977780 · 460 participants · Phase 2

    INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

  • NCT03427736 · 460 participants

    Anesthetics and Analgesics in Children

  • NCT03819933 · 460 participants · NA

    Optimizing Family Counseling for Anticipated Extremely Preterm Delivery

  • NCT04621279 · 460 participants

    Cool Prime Comparative Effectiveness Study for Mild HIE

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07253285

Source: ClinicalTrials.gov NCT07253285, the US trial registry maintained by the National Library of Medicine. NCT07253285 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.